Effect of Elexacaftor/Tezacaftor/Ivacaftor on
Pseudomonas
cystic fibrosis
tobramycin
Journal
The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
ISSN: 1551-6776
Titre abrégé: J Pediatr Pharmacol Ther
Pays: United States
ID NLM: 101089851
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
25
10
2022
accepted:
29
03
2023
medline:
10
4
2024
pubmed:
10
4
2024
entrez:
10
4
2024
Statut:
ppublish
Résumé
As cystic fibrosis (CF) lung disease progresses, the airways become infected with opportunistic pathogens, such as A retrospective analysis of inhaled tobramycin (iTOB) prescriptions between January 1, 2016, and December 31, 2021, was performed. This captured data before and after ETI approval at Children's Mercy Kansas City (CMKC). The number of individuals with new PA acquisition and individuals considered -chronically infected was analyzed. The number of eradication prescriptions declined in 2020 and 2021, with 15 (7%) and 12 (5%) -individuals prescribed therapy for those years, respectively. A similar pattern was observed for -prescriptions for chronic infection. A reduction was seen in 2020 and 2021, with 28 (13%) and 20 (9%) individuals -prescribed therapy for the respective years. The CMKC experienced a decrease in the number of courses of iTOB prescribed during the last 6 years. The reasons for this are likely multifactorial and may include the implementation of standardized PA surveillance and eradication protocols, the effect of HEMT on mucociliary clearance and airway microbiology, and the poorly understood effects of the SARS-CoV-2 pandemic on the epidemiology of respiratory infections.
Identifiants
pubmed: 38596420
doi: 10.5863/1551-6776-29.2.135
pmc: PMC11001205
doi:
Types de publication
Journal Article
Langues
eng
Pagination
135-139Informations de copyright
Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org.
Déclaration de conflit d'intérêts
Disclosures. The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. The authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.